LISRAYA (Brepocitinib Tosylate) Patent Expiration, LOE Window & CMS Spending

LISRAYA (Brepocitinib Tosylate) by Priovant Therapeutics: FDA Orange Book core substance LOE 2035-08-19, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $35,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPriovant Therapeutics
FDA Application & PathwayN220106 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-08-19
Last Listed Patent or Exclusivity Date2035-08-19
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($35,000 intro WAC)